Skip to main content

Drug Interactions between apomorphine and selexipag

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

apomorphine selexipag

Applies to: apomorphine and selexipag

MONITOR CLOSELY: Apomorphine may potentiate the hypotensive effect of vasodilators and antihypertensive agents. Apomorphine alone has been associated with orthostatic hypotension, hypotension, syncope, and dose-dependent decreases in systolic and diastolic blood pressure. In clinical studies of the subcutaneous formulation of apomorphine in patients with advanced Parkinson's disease, hypotension (10% vs 4%), myocardial infarction (3% vs. 1%), serious pneumonia (5% vs. 3%), serious falls (9% vs. 3%), and bone and joint injuries (6% vs. 2%) were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n=94) compared to those not receiving these medications (n=456). Some of these events may be related to the increased incidence of hypotension.

MANAGEMENT: Caution and close monitoring for altered efficacy and safety are recommended if patients receive apomorphine with an antihypertensive agent or vasodilator. Some authorities consider the combination of subcutaneous apomorphine with antihypertensive medications or vasodilators to be contraindicated due to a lack of data from studies that systematically evaluated the potential interaction between apomorphine and these agents. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks. They should also be advised to avoid rising abruptly from a sitting or recumbent position and to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.

References

  1. "Product Information. Apokyn (apomorphine)." Mylan Pharmaceuticals Inc (2004):
  2. "Product Information. Apokyn (apomorphine)." US WorldMeds LLC (2022):
  3. "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Inc (2022):
  4. "Product Information. Movapo (apomorphine)." Paladin Labs Inc 2.0 (2023):
  5. "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Canada Inc (2022):
  6. "Product Information. Dacepton (apomorphine)." Ever Pharma UK Ltd (2024):
  7. "Product Information. aPomine Intermittent (apomorphine)." Pfizer Australia Pty Ltd 1.1 (2024):
  8. "Product Information. Movapo (apomorphine)." Stada Pharmaceuticals Australia Pty Ltd (2024):
View all 8 references

Switch to consumer interaction data

Drug and food interactions

Minor

selexipag food

Applies to: selexipag

Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.

References

  1. "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc (2016):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.